Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice

References

• McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414–430. doi:10.1093/ndt/gfq665
   PubMed Web of Science ®Google Scholar
• Schena FP, Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018;38(5):435–442. doi:10.1016/j.semnephrol.2018.05.013
   PubMed Web of Science ®Google Scholar
• Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727–738. doi:10.2215/CJN.0000000000000135
   PubMed Web of Science ®Google Scholar
• Kwon CS, Daniele P, Forsythe A, Ngai C. A systematic literature review of the epidemiology, health-related quality of life impact, and economic burden of immunoglobulin a nephropathy. J Health Econ Outcomes Res. 2021;8(2):36–45. doi:10.36469/jheor.2021.26129
   PubMedGoogle Scholar
• Magistroni R, D’Agati VD, Appel GB, Kiryluk K. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int. 2015;88(5):974–989. doi:10.1038/ki.2015.252
   PubMed Web of Science ®Google Scholar
• Trachtman H, Hogan JJ, Tesar V, Komers RS. Sparsentan. dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, treatment of focal segmental glomerulosclerosis, treatment of IgA nephropathy. Drugs Future. 2020;45(2):79–98. doi:10.1358/dof.2020.45.2.3058863
   Web of Science ®Google Scholar
• Rodrigues JC, Haas M, Reich HN. IgA nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677–686. doi:10.2215/CJN.07420716
   PubMed Web of Science ®Google Scholar
• Kohan DE, Barton M. Endothelin and endothelin antagonists in chronic kidney disease. Kidney Int. 2014;86(5):896–904. doi:10.1038/ki.2014.143
   PubMed Web of Science ®Google Scholar
• Lehrke I, Waldherr R, Ritz E, Wagner J. Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria. J Am Soc Nephrol. 2001;12(11):2321–2329. doi:10.1681/ASN.V12112321
   PubMed Web of Science ®Google Scholar
• Kohan DE, Pritchett Y, Molitch M, et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol. 2011;22(4):763–772. doi:10.1681/ASN.2010080869
   PubMed Web of Science ®Google Scholar
• Komers R, Plotkin H. Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease. Am J Physiol Regul Integr Comp Physiol. 2016;310(10):R877–R884. doi:10.1152/ajpregu.00425.2015
   PubMed Web of Science ®Google Scholar
• Barton M, Tharaux PL. Endothelin and the podocyte. Clin Kidney J. 2012;5(1):17–27. doi:10.1093/ckj/sfs001
   PubMedGoogle Scholar
• Siragy HM, Carey RM. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol. 2010;31(6):541–550. doi:10.1159/000313363
   PubMed Web of Science ®Google Scholar
• Kohan DE, Rossi NF, Inscho EW, Pollock DM. Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev. 2011;91(1):1–77. doi:10.1152/physrev.00060.2009
   PubMed Web of Science ®Google Scholar
• Lai KN, Tang SC, Schena FP, et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2:16001. doi:10.1038/nrdp.2016.1
   PubMed Web of Science ®Google Scholar
• Raina R, Chauvin A, Chakraborty R, et al. The role of endothelin and endothelin antagonists in chronic kidney disease. Kidney Dis. 2020;6(1):22–34. doi:10.1159/000504623
   Google Scholar
• Chan LY, Leung JC, Tang SC, Choy CB, Lai KN. Tubular expression of angiotensin II receptors and their regulation in IgA nephropathy. J Am Soc Nephrol. 2005;16(8):2306–2317. doi:10.1681/ASN.2004121117
   PubMed Web of Science ®Google Scholar
• Benigni A, Buelli S, Kohan DE. Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition. Pediatr Nephrol. 2021;36(4):763–775. doi:10.1007/s00467-020-04518-2
   PubMed Web of Science ®Google Scholar
• Lin YJ, Kwok CF, Juan CC, et al. Angiotensin II enhances endothelin-1-induced vasoconstriction through upregulating endothelin type A receptor. Biochem Biophys Res Commun. 2014;451(2):263–269. doi:10.1016/j.bbrc.2014.07.119
   PubMed Web of Science ®Google Scholar
• Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int. 2021;100(4s):S1–S276. doi:10.1016/j.kint.2021.05.021
   PubMed Web of Science ®Google Scholar
• Sharma S, Smyth B. From proteinuria to fibrosis: an update on pathophysiology and treatment options. Kidney Blood Press Res. 2021;46(4):411–420. doi:10.1159/000516911
   PubMed Web of Science ®Google Scholar
• Kohan DE, Inscho EW, Wesson D, Pollock DM. Physiology of endothelin and the kidney. Compr Physiol. 2011;1(2):883–919.
   PubMed Web of Science ®Google Scholar
• Reich HN, Troyanov S, Scholey JW, Cattran DC. Toronto glomerulonephritis registry. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18(12):3177–3183. doi:10.1681/ASN.2007050526
   PubMed Web of Science ®Google Scholar
• Calliditas Therapeutics AB. TARPEYO (budesonide) delayed release capsules, for oral use [prescribing information]. Stockholm, Sweden; 2021.
   Google Scholar
• Stefan G, Mircescu G. Hydroxychloroquine in IgA nephropathy: a systematic review. Ren Fail. 2021;43(1):1520–1527. doi:10.1080/0886022X.2021.2000875
   PubMed Web of Science ®Google Scholar
• Wheeler DC, Toto RD, Stefánsson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100(1):215–224. doi:10.1016/j.kint.2021.03.033
   PubMed Web of Science ®Google Scholar
• Ayoub I, Komers R, Mercer A, Preciado P, Tang SC, Rovin BH. Sparsentan and sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the PROTECT open-label extension (OLE) substudy and SPARTACUS: trials in progress [Abstract]. J Am Soc Nephrol. 2023;24:979.
   Google Scholar
• Kooienga L, Malecki R, Preciado P, He P, Mercer A. On behalf of the DUPRO steering committee. Concomitant sparsentan and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in patients with IgA nephropathy (IgAN) in the PROTECT open-label extension (OLE) [Abstract]. J Am Soc Nephrol. 2023;24:979.
   Google Scholar
• Travere Therapeutics, Inc. FILSPARI™ (sparsentan) tablets, for oral use [prescribing information]. San Diego, CA; 2023.
   Google Scholar
• Coppo R, Amore A, Gianoglio B, et al. Angiotensin II local hyperreactivity in the progression of IgA nephropathy. Am J Kidney Dis. 1993;21(6):593–602. doi:10.1016/S0272-6386(12)80031-X
   PubMed Web of Science ®Google Scholar
• Boels MG, Avramut MC, Koudijs A, et al. Atrasentan reduces albuminuria by restoring the glomerular endothelial glycocalyx barrier in diabetic nephropathy. Diabetes. 2016;65(8):2429–2439. doi:10.2337/db15-1413
   PubMed Web of Science ®Google Scholar
• Nagasawa H, Suzuki H, Jenkinson C, et al. MO261: sparsentan, the dual endothelin angiotensin receptor antagonist (DEARA), attenuates albuminuria and protects from the development of renal injury to a greater extent than losartan in the GDDY mouse model of IgA nephropathy: a 16-week study [abstract]. Nephrol Dial Transplant. 2022;37(suppl_3):gfac067–060.
   Google Scholar
• Reily C, Moldoveanu Z, Pramparo T, et al. The dual endothelin angiotensin receptor antagonist (DEARA) sparsentan protects from glomerular hypercellularity and associated immune/inflammatory gene-network-activity in a model of IgA nephropathy (IgAN) [abstract]. J Am Soc Nephrol. 2021;32:459. doi:10.1681/ASN.2020060833
   PubMedGoogle Scholar
• Gyarmati G, Deepak SK, Shroff UN, et al. Sparsentan improves glomerular endothelial and podocyte functions and augments protective tissue repair in a mouse model of focal segmental glomerulosclerosis (FSGS) [abstract]. J Am Soc Nephrol. 2022;33:839–79.
   PubMedGoogle Scholar
• Bedard P, Jenkinson C, Komers R. MO255: sparsentan protects the glomerular basement membrane and glycocalyx, and attenuates proteinuria in a rat model of focal segmental glomerulosclerosis (FSGS) [abstract]. Nephrol Dial Transplant. 2022;37(suppl_3):gfac067.054. doi:10.1093/ndt/gfac067.054
   Google Scholar
• Cosgrove D, Gratton MA, Madison J, et al. Dual inhibition of the endothelin and angiotensin receptor ameliorates renal and inner ear pathologies in Alport mice. J Pathol. 2023;260(3):353–364. doi:10.1002/path.6087
   PubMed Web of Science ®Google Scholar
• Barratt J, Rovin B, Diva U, Mercer A, Komers R. Implementing the kidney health initiative surrogate efficacy endpoint in patients with IgA nephropathy (the PROTECT trial). Kidney Int Rep. 2019;4(11):1633–1637. doi:10.1016/j.ekir.2019.08.007
   PubMed Web of Science ®Google Scholar
• Barratt J, Rovin B, Wong MG, et al. IgA nephropathy patient baseline characteristics in the sparsentan PROTECT study. Kidney Int Rep. 2023;8(5):1043–1056. doi:10.1016/j.ekir.2023.02.1086
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Radhakrishnan J, Alpers CE, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet. 2023;401(10388):1584–1594. doi:10.1016/S0140-6736(23)00569-X
   PubMed Web of Science ®Google Scholar
• Rovin BH, Barratt J, Heerspink HJL, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023;402:2077–90.
   PubMed Web of Science ®Google Scholar
• Thompson A, Carroll K, Inker LA, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019;14(3):469–481. doi:10.2215/CJN.08600718
   PubMed Web of Science ®Google Scholar
• Carroll K, Conley L, Mercer A, Saleem MA, Barratt J. Estimating delay in time to ESKD for treatment effects on proteinuria in IGA nephropathy and FSGS [abstract]. Nephrol Dial Transplant. 2021;36(suppl 1):gfab104.004. doi:10.1093/ndt/gfab104.004
   PubMedGoogle Scholar
• Hogan J, Derebail VK, Murphy E, et al. Long-term effects of sparsentan, a dual angiotensin and endothelin receptor antagonist in primary focal segmental glomerulosclerosis (FSGS): interim 84-week analysis of the DUET trial [abstract]. J Am Soc Nephrol. 2018;29(suppl):61.
   Google Scholar
• Hogan J, Diva U, Murphy E, Rosenberg N, Trachtman H, Komers R. Complete remission of proteinuria in patients with focal segmental glomerulosclerosis treated with sparsentan, a dual endothelin and angiotensin receptor antagonist, in the DUET trial. J Am Soc Nephrol. 2020;31(suppl):55.
   Google Scholar
• Trachtman H, Nelson P, Adler S, et al. DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol. 2018;29(11):2745–2754. doi:10.1681/ASN.2018010091
   PubMed Web of Science ®Google Scholar
• Rheault MN, Alpers CE, Barratt J, et al. Sparsentan versus irbesartan in focal segmental glomerulosclerosis. N Engl J Med. 2023. doi:10.1056/NEJMoa2308550
   PubMed Web of Science ®Google Scholar
• Chen S-C, Cai D, Winnett C, et al. Effect of multiple doses of sparsentan on the single-dose pharmacokinetics of dapagliflozin: an open-label drug–drug interaction study in healthy adults. Clin Pharmacol Drug Dev. 2023;12(5):535–541. doi:10.1002/cpdd.1231
   PubMed Web of Science ®Google Scholar
• Schöll U, Wastl U, Risler T, et al. The ”point of no return” and the rate of progression in the natural history of IgA nephritis. Clin Nephrol. 1999;52(5):285–292.
   PubMed Web of Science ®Google Scholar
• Komatsu H, Fujimoto S, Sato Y, et al. ”Point of no return (PNR)” in progressive IgA nephropathy: significance of blood pressure and proteinuria management up to PNR. J Nephrol. 2005;18(6):690–695.
   PubMed Web of Science ®Google Scholar
• Arora N, Katz R, Bansal N. ACE inhibitor/angiotensin receptor blocker use patterns in advanced CKD and risk of kidney failure and death. Kidney Med. 2020;2(3):248–257. doi:10.1016/j.xkme.2019.12.007
   PubMedGoogle Scholar